The mechanism of action of Apremilast/Apremilast tablets

Apremilast/Apremilast tablets are a highly selective phosphodiesterase-4 (PDE-4) inhibitor. PDE-4 is an important enzyme in cells, responsible for hydrolyzing cyclic adenosine monophosphate (cAMP), thereby reducing its intracellular concentration. cAMPAs a second messenger, it participates in the regulation of various physiological and pathological processes in cells. Apremilast inhibits the activity of PDE-4 and reduces the hydrolysis of cAMP, thereby increasing the level of cAMP in cells.

IntracellularThe increase in cAMP levels further activates a series of downstream signaling pathways that play a key role in regulating inflammatory responses. Specifically, cAMP can inhibit the production and release of pro-inflammatory factors, such as tumor necrosis factor (TNF-α), interleukin (< span>IL)-1, IL-6, etc. These factors play an important role in the pathogenesis of psoriasis. At the same time, cAMP can also promote the expression of anti-inflammatory factors, thereby reducing inflammatory response and tissue damage.

Based on the above mechanism of action, Apremilast has shown significant efficacy in the treatment of psoriasis. Psoriasis is a chronic autoimmune disease with complex pathogenesis involving abnormal activation of the immune system and inflammatory response. Apremilast can effectively control the development of psoriasis, reduce skin lesion symptoms, and improve patients' quality of life by inhibiting PDE-4, increasing cAMP levels, and regulating inflammatory responses.

Multiple clinical studies have confirmed the efficacy and safety of Apremilast in the treatment of psoriasis. For example, in an item named ADVANCE3In a phase 1 clinical study, researchers evaluated the efficacy and safety of apremilast in the treatment of patients with mild to moderate psoriasis. The results showed that compared with the placebo group, the apremilast group showed significant advantages in multiple efficacy indicators and had a good safety profile.